Praxis Precision Medicines Inc
PRAX55.650USD
0.0000.00%
收盤 07/28, 16:00（美東）報價延遲15分鐘
1.13B總市值
虧損本益比TTM
關於 Praxis Precision Medicines Inc 公司
Praxis Precision Medicines, Inc. 是一家臨牀階段的生物製藥公司。該公司專注於將對遺傳性癲癇的洞察轉化爲以神經元興奮-抑制失衡爲特徵的中樞神經系統疾病的治療方法的開發。該公司利用對大腦中共同的生物靶點和迴路的理解，通過兩個平臺將遺傳學見解應用於神經系統疾病療法的發現和開發。其平臺包括 Cerebrum，這是一個小分子平臺，利用對神經元興奮性和神經元網絡的深入瞭解，並應用一系列計算和實驗工具來開發口服精準療法；Solidus 是一個反義寡核苷酸平臺，是一種基於專有計算方法的高效、有針對性的精準藥物發現和開發引擎。其候選產品包括 ulixacaltamide、PRAX-562、PRAX-628 和 elsunersen。
公司簡介
公司代碼PRAX
公司名稱Praxis Precision Medicines Inc
上市日期Oct 16, 2020
成立日期2015
CEOMr. Marcio Souza
員工數量116
證券類型Ordinary Share
年結日Oct 16
公司地址99 High Street, 30th Floor
城市BOSTON
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編02110
電話16173008460
網址https://praxismedicines.com/
公司代碼PRAX
上市日期Oct 16, 2020
成立日期2015
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Alex Nemiroff, J.D.
Mr. Alex Nemiroff, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
3.94K
-80.31%
Ms. Jill Desimone
Ms. Jill Desimone
Independent Director
Independent Director
966.00
--
Mr. Gregory (Greg) Norden
Mr. Gregory (Greg) Norden
Independent Director
Independent Director
188.00
--
Mr. William Young
Mr. William Young
Independent Director
Independent Director
--
--
Mr. Marcio Souza
Mr. Marcio Souza
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Dean Mitchell
Mr. Dean Mitchell
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Timothy E. (Tim) Kelly
Mr. Timothy E. (Tim) Kelly
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Jeffrey A. (Jeff) Chodakewitz, M.D.
Dr. Jeffrey A. (Jeff) Chodakewitz, M.D.
Independent Director
Independent Director
--
--
Dr. Merit Cudkowicz, M.D.
Dr. Merit Cudkowicz, M.D.
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Alex Nemiroff, J.D.
Mr. Alex Nemiroff, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
3.94K
-80.31%
Ms. Jill Desimone
Ms. Jill Desimone
Independent Director
Independent Director
966.00
--
Mr. Gregory (Greg) Norden
Mr. Gregory (Greg) Norden
Independent Director
Independent Director
188.00
--
Mr. William Young
Mr. William Young
Independent Director
Independent Director
--
--
Mr. Marcio Souza
Mr. Marcio Souza
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Dean Mitchell
Mr. Dean Mitchell
Independent Chairman of the Board
Independent Chairman of the Board
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 6月11日 週三
更新時間: 6月11日 週三
持股股東
股東類型
持股股東
持股股東
佔比
Janus Henderson Investors
11.29%
Cormorant Asset Management, LP
8.57%
Adage Capital Management, L.P.
8.56%
Perceptive Advisors LLC
6.69%
BlackRock Institutional Trust Company, N.A.
6.29%
Other
58.61%
持股股東
持股股東
佔比
Janus Henderson Investors
11.29%
Cormorant Asset Management, LP
8.57%
Adage Capital Management, L.P.
8.56%
Perceptive Advisors LLC
6.69%
BlackRock Institutional Trust Company, N.A.
6.29%
Other
58.61%
股東類型
持股股東
佔比
Hedge Fund
42.46%
Investment Advisor
31.95%
Investment Advisor/Hedge Fund
27.63%
Research Firm
8.89%
Private Equity
6.69%
Venture Capital
6.52%
Sovereign Wealth Fund
0.58%
Bank and Trust
0.22%
Pension Fund
0.22%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
340
24.94M
122.42%
-159.68K
2025Q1
354
23.88M
117.36%
-1.32M
2024Q4
340
21.98M
109.07%
-1.43M
2024Q3
328
19.19M
107.78%
-2.59M
2024Q2
309
18.51M
104.24%
+1.04M
2024Q1
301
15.97M
96.49%
+5.95M
2023Q4
275
8.07M
91.87%
-1.62M
2023Q3
277
7.85M
94.33%
-1.72M
2023Q2
277
8.02M
96.64%
+3.13M
2023Q1
273
3.78M
97.85%
-268.38K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Janus Henderson Investors
2.30M
11.29%
+793.79K
+52.69%
May 30, 2025
Cormorant Asset Management, LP
1.75M
8.57%
+51.78K
+3.06%
Mar 31, 2025
Adage Capital Management, L.P.
1.74M
8.56%
+1.14M
+188.05%
Mar 31, 2025
Perceptive Advisors LLC
980.89K
4.82%
-348.84K
-26.23%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.28M
6.29%
-59.65K
-4.45%
Mar 31, 2025
Soleus Capital Management, L.P.
1.14M
5.6%
+896.20K
+367.99%
Mar 31, 2025
Morgan Stanley & Co. LLC
1.10M
5.41%
+21.46K
+1.99%
Mar 31, 2025
The Vanguard Group, Inc.
1.08M
5.32%
+23.38K
+2.21%
Mar 31, 2025
T. Rowe Price Associates, Inc.
1.07M
5.25%
-113.46K
-9.59%
Mar 31, 2025
VR Adviser, LLC
989.99K
4.86%
--
--
Mar 31, 2025
查看更多
持股ETF
更新時間: 7月6日 週日
更新時間: 7月6日 週日
機構名稱
佔比
iShares Neuroscience and Healthcare ETF
1.72%
Global X Genomics & Biotechnology ETF
1.01%
Virtus LifeSci Biotech Clinical Trials ETF
0.87%
ALPS Medical Breakthroughs ETF
0.69%
Tema Neuroscience and Mental Health ETF
0.4%
SPDR S&P Biotech ETF
0.27%
Direxion Daily S&P Biotech Bull 3X Shares
0.16%
iShares Micro-Cap ETF
0.15%
ProShares Ultra Nasdaq Biotechnology
0.1%
Invesco Nasdaq Biotechnology ETF
0.09%
查看更多
iShares Neuroscience and Healthcare ETF
佔比1.72%
Global X Genomics & Biotechnology ETF
佔比1.01%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.87%
ALPS Medical Breakthroughs ETF
佔比0.69%
Tema Neuroscience and Mental Health ETF
佔比0.4%
SPDR S&P Biotech ETF
佔比0.27%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.16%
iShares Micro-Cap ETF
佔比0.15%
ProShares Ultra Nasdaq Biotechnology
佔比0.1%
Invesco Nasdaq Biotechnology ETF
佔比0.09%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Nov 22, 2023
Merger
15<1
Nov 22, 2023
Merger
15<1
Nov 22, 2023
Merger
15<1
Nov 22, 2023
Merger
15<1
公告日期
類型
比率
Nov 22, 2023
Merger
15<1
Nov 22, 2023
Merger
15<1
Nov 22, 2023
Merger
15<1
Nov 22, 2023
Merger
15<1
